Kxone-SL 500mg/125mg Injection
Marketer
Kalpataru Formulations Pvt Ltd
Salt Composition
Ceftriaxone (500mg) + Sulbactam (125mg)
Overview Kxone-SL 500mg/125mg Injection
Combiflox-500 Injection, a dual-action medication (500mg/125mg), combats diverse bacterial infections. Its mechanism inhibits microbial proliferation, curbing infection spread. Administration should strictly follow a healthcare provider's instructions; consistently adhere to the prescribed schedule. Complete the entire treatment course, regardless of symptom improvement; premature cessation may compromise efficacy. Potential side effects include nausea, vomiting, diarrhea, and dyspepsia. Report any worsening side effects immediately. Seek urgent medical attention for allergic reactions (rash, pruritus, edema, dyspnea). Disclose all current medications to your physician before commencing treatment. Pregnant or lactating individuals require prior medical consultation. Alcohol consumption should be avoided due to potential increased drowsiness. While usually non-impairing to driving ability, refrain from driving if drowsiness or dizziness occurs. Adequate rest, nutritious food, and sufficient hydration are crucial for optimal recovery. Your doctor might order lab tests and diagnostics to monitor the medicine's effects.
Primary Ingredients of Kxone-SL 500mg/125mg Injection
No text provided to rephrase.
Uses of Kxone-SL 500mg/125mg Injection
Infections caused by bacteria
Major Benefits of Kxone-SL 500mg/125mg Injection:
Administering this medication will be handled by your physician or their qualified associate; please do not attempt self-medication.
Common Side effects of Kxone-SL 500mg/125mg Injection:
- Increased white blood cell count (eosinophils)
- Decreased white blood cell count (lymphocytes)
- Low blood platelets
- Rash
- Diarrhea
- Increased liver enzymes
- Injection site reactions (pain, swelling, redness)
How to use Kxone-SL 500mg/125mg Injection:
This medication will be administered by your physician or their qualified assistant; self-medication is strictly prohibited.
How Kxone-SL 500mg/125mg Injection works:
Ceftriaxone and Sulbactam, combined as Kxone-SL 500mg/125mg Injection, offer a targeted antibacterial approach. Ceftriaxone, a cephalosporin antibiotic, disrupts bacterial cell wall synthesis, hindering their growth and survival. Sulbactam, a beta-lactamase inhibitor, counters bacterial resistance mechanisms, thereby boosting Ceftriaxone's effectiveness.
SAFETY ADVICE
AlcoholSAFE
There are no known adverse reactions from combining Kxone-SL 500mg/125mg Injection with alcohol.
PregnancySAFE IF PRESCRIBED
The injectable medication Kxone-SL (500mg/125mg) is usually deemed safe for pregnant individuals. Preclinical trials using animals revealed minimal or no negative consequences for fetal development; nevertheless, data from human trials are scarce.
Breast feedingCAUTION
Administering Kxone-SL 500mg/125mg Injection to breastfeeding mothers requires careful consideration. Lactation should be temporarily discontinued throughout the mother's treatment course and until the medication is fully cleared from her system.
DrivingUNSAFE
The administration of Kxone-SL 500mg/125mg Injection can induce drowsiness, blurred vision, and dizziness. Refrain from operating a vehicle if these effects manifest.
KidneyCONSULT YOUR DOCTOR
Data on Kxone-SL 500mg/125mg Injection use in individuals with renal impairment is scarce. Physician consultation is advised.
LiverCAUTION
Patients with severe hepatic impairment should use the Kxone-SL 500mg/125mg Injection cautiously, potentially requiring dosage modification. Physician consultation is advised. Dosage alteration for Kxone-SL 500mg/125mg Injection isn't suggested for individuals with mild to moderate liver dysfunction.
What if you forget to take Kxone-SL 500mg/125mg Injection :
Omit a dose of Kxone-SL 500mg/125mg Injection? Seek medical advice immediately.
Facts to Know About Kxone-SL 500mg/125mg Injection
| Label | Value |
|---|---|
| Developing Habits | No. |
| Type of Therapy | Antimicrobials |
3,018 People bought this recently